BIOMIMESYS® has taken place in the panel of the future medicine on the 27th of September. The next step has arrived, and Nathalie Maubon CEO of HCS Pharma has taken BIOMIMESYS® all the way to Asia. Our innovative and reliable 3D cell culture system is adapted to high throughput formats Read more…
We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 21th 2023. Title: 3D cell culture taking into account the extracellular matrix for phenotypic screening in the frame of Parkinson’s disease V. De Conto 1*, Cheung V.1, Alejandra Mogrovejo – Valdivia1, Maubon N.1, Vandenhaute E.1, Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 20th 2023. Title: 3D cell culture taking into account the extracellular matrix for bridging the gap between in vitro & in vivo: focus on cancer models V. De Conto 1 *, M. Fernandes2, J. Cicero, Read more…
Poster presented during the SLAS event in San Diego on the 27th and 28th of February 2023. Title: BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific Extracellular Matrix for Relevant Phenotypic Screening Dr. Nathalie Maubon*, Dr. Véronique De Conto, Dr. Méryl Roudaut, Dr Alejandra Mogrovejo – Valdivia, Julien Leriche, Vaihere Cheung and Dr Read more…
End of last year, the american legislation has ratified that new drugs no longer need to be tested in animals to receive Food and Drug Administration (FDA) approval. This is a huge step toward animal-free validation of drugs, but it requires the design of a relevant and more predictive drug Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of Read more…
Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix Read more…
There are several products today for 3D cell culture and many could be considered as “hydrogels”. In this short article, we explain differences between BIOMIMESYS® and hydrogels to help you to choose the right product for your very specific needs. In 3D cell cultures, many hydrogels could be used like Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…
We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…
Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The Read more…
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route to reach the central nervous system, several strategies have been developed. Among them, researchers try Read more…
